Safety, tolerability, and effectiveness of anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasia.
anticoagulation
antiplatelet
antithrombotic
epistaxis
gastrointestinal bleeding
hereditary hemorrhagic telangiectasia
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
19
07
2022
revised:
11
09
2022
accepted:
29
09
2022
pmc-release:
01
01
2024
entrez:
25
1
2023
pubmed:
26
1
2023
medline:
27
1
2023
Statut:
ppublish
Résumé
Antithrombotic therapy (anticoagulation and antiplatelet therapy) is frequently needed in patients with hereditary hemorrhagic telangiectasia (HHT); however, data describing and guiding its use are very limited. To investigate the safety, tolerability, and effectiveness of antithrombotic therapy in HHT in a cohort large enough to compare agents, evaluate for baseline predictors of premature discontinuation, and evaluate hematologic support requirements and healthcare utilization before and after antithrombitc therapy initiation. We performed a multicenter observational cohort study characterizing the outcomes of antithrombic therapy in adults with HHT. A total of 119 patients with HHT with 187 discrete antithrombotic therapy episodes were included. Of these, 59 patients (50%) dose-reduced and/or prematurely discontinued therapy (including 52 patients [44%] who discontinued) due to worsened bleeding complications. Initiation at reduced dose intensity had a similar premature discontinuation rate (49%) as initiation at standard dose intensity (43%). In a multivariable logistic model, a history of gastrointestinal bleeding was associated with 3.25-fold odds of discontinuation (p = .001). Hemoglobin was significantly lower (10.8 g/dL vs 12.2 g/dL, p < .001), and the need for hematologic support (intravenous iron and/or red blood cell transfusion) was significantly higher (29 patients vs 12 patients, p = .004) in the 3 months after antithrombotic therapy initiation vs the 3 months before; emergency department visits and hospital admissions due to bleeding also increased. The rates of dose-reduction and/or premature discontinuation were similar regardless of the anticoagulant class (warfarin, 46%; heparin-based, 48%; direct oral anticoagulants, 44%) or with multiple simultaneous agents (44%) but were slightly lower with single-agent antiplatelet therapy (37%). Thromboembolism despite receiving antithrombotic therapy was common (18 patients, 15%) with varying outcomes. Antithrombotic therapy is challenging in HHT, resulting in objectively higher morbidity and health care utilization from worsened bleeding. Discontinuation rates approached 50% regardless of the dose intensity at initiation or type of antithrombotic agent used and were higher in patients with a gastrointestinal bleeding history.
Sections du résumé
BACKGROUND
Antithrombotic therapy (anticoagulation and antiplatelet therapy) is frequently needed in patients with hereditary hemorrhagic telangiectasia (HHT); however, data describing and guiding its use are very limited.
OBJECTIVES
To investigate the safety, tolerability, and effectiveness of antithrombotic therapy in HHT in a cohort large enough to compare agents, evaluate for baseline predictors of premature discontinuation, and evaluate hematologic support requirements and healthcare utilization before and after antithrombitc therapy initiation.
METHODS
We performed a multicenter observational cohort study characterizing the outcomes of antithrombic therapy in adults with HHT.
RESULTS
A total of 119 patients with HHT with 187 discrete antithrombotic therapy episodes were included. Of these, 59 patients (50%) dose-reduced and/or prematurely discontinued therapy (including 52 patients [44%] who discontinued) due to worsened bleeding complications. Initiation at reduced dose intensity had a similar premature discontinuation rate (49%) as initiation at standard dose intensity (43%). In a multivariable logistic model, a history of gastrointestinal bleeding was associated with 3.25-fold odds of discontinuation (p = .001). Hemoglobin was significantly lower (10.8 g/dL vs 12.2 g/dL, p < .001), and the need for hematologic support (intravenous iron and/or red blood cell transfusion) was significantly higher (29 patients vs 12 patients, p = .004) in the 3 months after antithrombotic therapy initiation vs the 3 months before; emergency department visits and hospital admissions due to bleeding also increased. The rates of dose-reduction and/or premature discontinuation were similar regardless of the anticoagulant class (warfarin, 46%; heparin-based, 48%; direct oral anticoagulants, 44%) or with multiple simultaneous agents (44%) but were slightly lower with single-agent antiplatelet therapy (37%). Thromboembolism despite receiving antithrombotic therapy was common (18 patients, 15%) with varying outcomes.
CONCLUSION
Antithrombotic therapy is challenging in HHT, resulting in objectively higher morbidity and health care utilization from worsened bleeding. Discontinuation rates approached 50% regardless of the dose intensity at initiation or type of antithrombotic agent used and were higher in patients with a gastrointestinal bleeding history.
Identifiants
pubmed: 36695393
pii: S1538-7836(22)07171-9
doi: 10.1016/j.jtha.2022.09.003
pmc: PMC10082473
mid: NIHMS1884187
pii:
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Fibrinolytic Agents
0
Anticoagulants
0
Types de publication
Observational Study
Multicenter Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
26-36Subventions
Organisme : NHLBI NIH HHS
ID : K23 HL159313
Pays : United States
Informations de copyright
Copyright © 2022 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.
Références
Haematologica. 2021 Aug 01;106(8):2161-2169
pubmed: 32675221
Orphanet J Rare Dis. 2019 Aug 9;14(1):196
pubmed: 31399146
Front Genet. 2015 Apr 09;6:101
pubmed: 25914716
Blood. 2021 Feb 18;137(7):888-895
pubmed: 33171488
Haematologica. 2018 Sep;103(9):1433-1443
pubmed: 29794143
Otolaryngol Head Neck Surg. 2019 Feb;160(2):368
pubmed: 30798765
BMC Res Notes. 2014 Apr 23;7:264
pubmed: 24758689
Ann Intern Med. 2021 Jul;174(7):1035-1036
pubmed: 34280351
Laryngoscope. 1991 Sep;101(9):977-80
pubmed: 1886446
Haematologica. 2021 Mar 01;106(3):661-663
pubmed: 33645945
J Clin Med. 2020 Jun 02;9(6):
pubmed: 32498318
Lancet Haematol. 2021 Jul;8(7):e472-e474
pubmed: 34171274
Ann Intern Med. 2021 Nov;174(11):1493-1502
pubmed: 34633836
Br J Haematol. 2019 May;185(4):764-767
pubmed: 30338508
Thromb Haemost. 2007 Nov;98(5):1031-9
pubmed: 18000608
Curr Opin Hematol. 1998 Sep;5(5):332-8
pubmed: 9776212
J Intern Med. 2019 Feb;285(2):223-231
pubmed: 30191646
Thromb Res. 2017 May;153:14-18
pubmed: 28314138
Angiogenesis. 2022 Feb;25(1):87-97
pubmed: 34292451
Thromb Res. 2018 Sep;169:41-43
pubmed: 30015226
Semin Thromb Hemost. 2022 Jul;48(5):514-528
pubmed: 35226946
Ann Hematol. 2012 Dec;91(12):1959-68
pubmed: 23053175
Am J Hematol. 2020 Jul 3;:
pubmed: 32619079
Thromb Res. 2021 Jan;197:109-111
pubmed: 33221575
J Thromb Haemost. 2022 May;20(5):1077-1088
pubmed: 35343049
Thorax. 2012 Apr;67(4):328-33
pubmed: 22169361
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Orphanet J Rare Dis. 2019 Aug 28;14(1):210
pubmed: 31462308
N Engl J Med. 2013 Feb 28;368(9):876-8
pubmed: 23445111
Haemophilia. 2020 Nov;26(6):1038-1045
pubmed: 32432841